Home » View latest Dosulepin Tenders from India

View latest Dosulepin Tenders from India

TendersOnTime provides latest updates on Indian Dosulepin Tenders from various state and central government tendering authorities. The information on Dosulepin online tenders and turnkey projects from India is collected from various sources viz: e procurement tenders list, newspapers and tender bulletin etc.

Country: India

Tablet. Dosulepin 75 Mg + Methylcobalami [Tablet. Dosulepin 75 Mg + Methylcobalamin 1500 Mcg]

TOT Ref No.: 100269576

Deadline: 06 May 2024

Country: India

Tab Dosulepin 50 Mg, Qty: 1200 Nos, (BOQ Item #69)

TOT Ref No.: 100086393

Deadline: 07 May 2024

Country: India

Procurement of Leflunomide 20Mg Tab, Clindamycin 300Mg Cap, Vancomycin 1G Inj, Dosulepin 25Mg Tab

TOT Ref No.: 100369158

Deadline: 09 May 2024

Country: India

Dosulepin 25 Mg Tab

TOT Ref No.: 99544825

Deadline: 22 Apr 2024

Country: India

Tablet. Dosulepin 75 Mg + Methylcobalami [Tablet. Dosulepin 75 Mg + Methylcobalamin 1500 Mcg]

TOT Ref No.: 98767998

Deadline: 26 Mar 2024

Country: India

Tablet. Dosulepin 75 Mg + Methylcobalami [Tablet. Dosulepin 75 Mg + Methylcobalamin 1500 Mcg]

TOT Ref No.: 99363159

Deadline: 15 Apr 2024

Country: India

A M i No. 14.162 / 2024-25 Tab/Cap. Dosulepin 75Mg

TOT Ref No.: 99316355

Deadline: 12 Apr 2024

Country: India

Dosulepin 25Mg Tab ( Ami 2024-25 Sl No. 921)

TOT Ref No.: 99531253

Deadline: 09 Apr 2024

Country: India

A M i No. 14.161 / 2024-25 Tab/Cap. Dosulepin 25Mg

TOT Ref No.: 99301758

Deadline: 10 Apr 2024

Country: India

Tab Dosulepin 25 Mg, Qty: 600 No, (BOQ Item #45)

TOT Ref No.: 96993693

Deadline: 26 Feb 2024

Country: {{rowDetails.Country_Name}}

TOT Ref No.: {{rowDetails.ID}}

Deadline: {{rowDetails.Bid_Deadline_1}}

Deadline: {{rowDetails.Bid_Deadline_1}}

No data Found!! Please search again

Browse Tenders

Browse Tenders from below Sections

Call Action

Get A Callback Within 24 Hours

Fill form below to get callback from Tender Experts.

Click button to send your details.